Policy update / November 2026
The Justice Department officially moved state-licensed medical marijuana to Schedule III through a limited April 2026 action covering qualifying state medical products and FDA-approved marijuana drug products. The Federal Register final rule gives April 28, 2026 as its effective date. Broader marijuana rescheduling has a separate administrative proceeding; the medical rule does not put every adult-use product into Schedule III.
For customers, the most useful distinction is between a federal classification and the rules governing a particular purchase. For businesses, state licensing, DEA registration and tax treatment remain separate questions. This is general information, not legal or tax advice.
Last reviewed: November 2026.
The Justice Department officially moved state-licensed medical marijuana to Schedule III: which products?
The April rule applies to marijuana included in an FDA-approved drug product or subject to a qualifying state license for medical manufacture, distribution or dispensing. Its scope also addresses covered extracts and plant-derived compounds. The qualifying medical context is essential; a generic statement that all state-licensed marijuana moved schedules is too broad.
DOJ’s April 23 announcement described both the medical action and the start of a separate process for broader rescheduling. The two appeared in the same announcement, which helps explain why headlines sometimes combine them. A completed action for one category and a proposed change for a wider category are different legal events.
Explore the categories separately
These panels summarize the April rule's scope. They do not determine the status of a particular product or business.
Covered
FDA-approved product
The April final rule addresses marijuana in FDA-approved drug products within its stated scope.
Covered
Qualifying state medical
The rule addresses marijuana subject to a qualifying state medical license, with federal requirements and a registration pathway.
Separate
Adult-use product
The limited medical action does not reclassify every adult-use product. Broader rescheduling has its own proceeding.
Review
Specific business
State designation, federal registration and the business’s actual activities require separate assessment by its advisers.
FDA approval also belongs to a specific drug product. A state medical license is a different basis addressed by the rule. Neither a product’s popularity nor the word medicinal on an informal description can replace the applicable record. When a question concerns a particular business or product, the actual license and federal requirements need review.
The broader DEA case has its own timeline
DEA’s October 22, 2026 procedural order records that the hearing on the broader proposal took place from June 29 through July 15. It admits a Government Accountability Office report into that record and denies a request to reopen the hearing for further testimony and discovery. Those procedural decisions do not themselves reschedule adult-use marijuana.
The order permits limited briefs about the GAO report, with briefs due October 29 and replies due November 5. It says the stay expires at the end of that briefing schedule. A reply deadline is not a promised date for a recommended decision or a final rule. Keep those events separate when reading an update dated around the close of briefing.
Follow the official dates
Medical rule and broader case: selected dates
Tap a date to see which process it belongs to.
April 28
Medical rule takes effect
The limited medical rescheduling final rule identifies April 28, 2026 as its effective date.
June 29
Broader hearing begins
The October order records hearings beginning June 29 and continuing through July 15.
Oct. 22
Procedural order issued
The judge admits the GAO report, allows limited briefing and denies reopening for new testimony.
Nov. 5
Replies are due
The order sets November 5 as the reply deadline and ties expiration of the stay to the end of briefing.
April effective date: Federal Register. Hearing and briefing dates: DEA October 22 order. A deadline does not predict a final outcome.
The order therefore supplies a concrete status point without predicting the outcome. The next legally relevant record would have to be read for what it actually decides. A procedural ruling, an agency recommendation and an effective final rule can each generate news while having different consequences.
State licensing and DEA registration remain distinct
California’s DCC maintains federal rescheduling resources that direct medicinal licensees to the DEA registration portal. Its page says DEA continues to accept applications after the initial expedition window, while applications submitted after June 26, 2026 do not qualify for that expedition provision. Eligibility and compliance questions still belong with the responsible agency and legal counsel.
Two tracks
One rule is in effect. The broader case is still open.
FDA-approved and state-licensed medical marijuanaIn effect
- Apr 23, 2026Justice Department announces the action
- Apr 28, 2026Final rule published at 91 FR 22714
- Apr 28, 2026Rule takes effect: Schedule III for this category
Broader rescheduling of marijuanaNot decided
- Jun 29 to Jul 15DEA hearing held
- Oct 22Order admits GAO report, denies reopening the hearing
- Oct 29 / Nov 5Briefs due, then replies
- No dateRecommended decision
- No dateAny final rule
- Taxes. Treasury and the IRS announced Section 280E guidance on April 23; the rule leaves each business's federal tax liability for further assessment.
- Licenses. A California state license and a DEA registration are separate. DCC says keep operating under your current designation until a state change is approved.
- Shoppers. Neither track sets a menu price or changes California's 21+ purchase rules.
Sources: Federal Register, 91 FR 22714 (April 28, 2026, docket DEA-1362); DOJ announcement, April 23, 2026; DEA order, October 22, 2026; Treasury press release, April 23, 2026; DCC federal rescheduling resources. Status as of the October 22, 2026 order. General information, not legal advice.
DCC also describes processes for changing a state license designation or requesting a separate medicinal retail license. Those state processes are not the same as federal registration. DCC instructs businesses to continue operating under their current designation until the state request is approved.
These distinctions prevent a common jump from a broad headline to an unsupported conclusion about an individual store. A store’s current status must come from its records. No Vibe location is represented here as holding a particular DEA registration, having changed its state designation or qualifying for a specific federal tax result.
What the tax announcements actually address
Section 280E concerns deductions and credits for businesses trafficking in Schedule I or II controlled substances. Treasury and the IRS’s April 23 announcement explains why a scheduling change can affect its application. It also discusses expected guidance for businesses with multiple activities, including how expenses may need to be apportioned.
The Federal Register rule expressly leaves individual federal tax liability for further assessment and tells state licensees to consult tax counsel. A business may have different activities and records to evaluate. That is why a headline about Schedule III cannot establish a refund, a deduction amount or a price reduction for every operator.
Customers should use the receipt and current store pricing for an actual purchase. The federal scheduling action is not a receipt calculation and supplies no guarantee that a menu price will change. The California cannabis laws guide covers the state framework separately.
What a California shopper can check today
Check the retailer’s state license and read the actual product information. The DCC consumer guide describes California purchase eligibility and licensed retail shopping. The state adult-use and medicinal categories remain relevant to a purchase even while the federal processes develop.
A medical recommendation, a state-issued card, a product’s federal classification and a business’s registration answer different questions. If a question affects your personal eligibility, travel or tax position, bring the relevant records to a qualified adviser. Avoid treating the word medical in a headline as a substitute for those documents.
Use the Vibe locations page for your store’s current menu and information. Before relying on a future rescheduling update, read its effective date and the products it actually covers. The date an announcement appears and the date a rule takes effect can differ.
Frequently asked questions
The April 2026 rule covers FDA-approved marijuana drug products and qualifying state medical marijuana within its stated scope. It does not reclassify every adult-use product; broader rescheduling has a separate administrative proceeding.
The October 22 order records hearings from June 29 through July 15, admits a GAO report and allows limited briefs without reopening the hearing. Replies were due November 5. That procedural deadline does not establish a final-rule date.
An individual result depends on the activities and applicable rules. Treasury described expected guidance, including mixed activities, and the final rule tells licensees to consult tax counsel. No blanket refund or deduction is established here.
Sources
- Federal Register: April medical rescheduling final rule
- DOJ: April 23, 2026 announcement
- DEA: October 22, 2026 procedural order
- DCC: federal rescheduling resources
- Treasury and IRS: April 23 tax-guidance announcement
- DCC: what is legal
For adults 21+ (18+ with a physician’s recommendation in California). Keep out of reach of children and pets. Do not drive or operate machinery after use.
Find the information for your Vibe store
Open your local store page for its current menu and contact details.